Plus Therapeutics (PSTV) Q4 2024 Annual Earnings
PSTV·Reported March 27, 2025·After market close
Plus Therapeutics reported Q4 2024 revenue of $1.4M, missed analyst consensus of $1.5M by $96.0K. Diluted EPS came in at $-0.67, missed the $-0.51 consensus by $0.16.
Revenue
$1.4Mmissed by $96.0K
Consensus: $1.5MDiluted EPS
$-0.67missed by $0.16
Consensus: $-0.51
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Plus Therapeutics's Q4 2024 earnings report.
Plus Therapeutics (PSTV) reported Q4 2024 earnings on March 27, 2025 after market close.
Plus Therapeutics reported revenue of $1.4M and diluted EPS of $-0.67 for Q4 2024.
Revenue missed the consensus estimate of $1.5M by $96.0K. EPS missed the consensus estimate of $-0.51 by $0.16.
You can read the 10-K periodic report (0000950170-25-047698) directly on SEC EDGAR. The filing index links above go to sec.gov.